The study to evaluate the efficacy and safety of Bipolar Radiofrequency-Assisted Lipolysis combined with Adjustable-depth fractional microneedle bipolar radiofrequency for periorbital Rejuvenation

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230417001

Enrollment

Registered

2023-04-17

Start date

2023-03-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Patient Bipolar Radiofrequency-Assisted Lipolysis,Adjustable-depth fractional microneedle bipolar radiofrequency,periorbital Rejuvenation

Interventions

Patients were treated with Accutite and Morpheus8 for 1 session then they were instructed to follow up at 1 month, 3 months, 6 months after the last treatments.

Experimental Device

Accutite and morpheus8

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 30-65 years 2. Both male and Female 3.Tear trough with mild to moderate skin laxity at eye

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant or lactation 2. Subjects who had history of low platelet, coagulopathy, anemia, liver disease, cancer, immunocompromised host or epilepsy 3. Subjects who has dermatits, wound or infection at treatment area 4. Subjects who allergy to anesthesia cream 5. Subjects who taken oral or injection contraceptive pills or coagulopathy drug 6. Subjects who had history of botulinum toxin treatment within 12 months before arrived the project 7. Subjects who had history of laser at treatment area within 6 months before arrived the project 8. Subjects who had history of keloid or hypertrophic scar 9. Subjects who had history of psychitic disease 10. Subjects who had metalic equipment in the body

Design outcomes

Primary

Measure	Time frame
Volume change Baseline, 1 month,3 months, 6 months Vectra	—

Secondary

Measure	Time frame
Skin Texture and Wrinkle Baseline, 1 month,3 months, 6 months Antera,Skin elasticity Baseline, 1 month,3 months, 6 months Cutometer,Doctor Evaluation Baseline, 1 month,3 months, 6 months Quatile Scale,Patient Evaluation Baseline, 1 month,3 months, 6 months Quatile scale,Pain Score Baseline Visual Analog Scale,safety Baseline, 1 month,3 months, 6 months Adverse Effect	—

Countries

Thailand

Contacts

Public ContactThanya Techapichetvanich

Faculty of Medicine Siriraj Hospital, Mahidol University

thanya.tec@gmail.com66837122248

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026